Study Summary
This trial looked at how well an ICD worked in people with heart disease.
- Ventricular Tachycardia
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
5 Primary · 4 Secondary · Reporting Duration: 3 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
PEFA targeted substrate ablation
1 of 1
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: PEFA VT ablation technique · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the primary aim of this investigation?
"The aim of this 3 year clinical trial is to reduce the amount of sustained ventricular tachycardia below a level that cannot be detected by an implantable cardioverter defibrillator (ICD). Secondary objectives include tracking changes in antiarrhythmic drug dosages due to efficacy or side effects, monitoring the total number of arrhythmias events over time, and measuring appropriate ATP from ICDs." - Anonymous Online Contributor
How many individuals are eligible for inclusion in this research project?
"Affirmative. According to the clinicaltrials.gov database, this experiment is currently open for recruitment and was initially posted on August 13th 2019 . 40 subjects are needed from 3 separate medical sites with the most recent update occurring on August 2nd 2022." - Anonymous Online Contributor
Is recruitment for this medical experiment still open?
"Correct. Data hosted on clinicaltrials.gov confirms that, as of August 2nd 2022, this medical study is actively seeking candidates for enrollment; the trial was initially posted back in August 2019 and requires 40 participants from 3 distinct sites." - Anonymous Online Contributor